N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP),
dizocilpine (MK-801) and ketamine have long been considered a model of schizophrenia …

1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor,
schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies …

Although glutamate was first hypothesized to be involved in the pathophysiology of
schizophrenia in the 1980s, it was the demonstration that N-methyl-D-aspartate (NMDA) …

Several attempts have been made to enhance N-methyl-D-aspartate (NMDA) receptor
function in schizophrenia, but they have yielded mixed results. Luvadaxistat, a D-amino acid …

Schizophrenia is a chronic, complex and heterogeneous mental disorder, with pathological
features of disrupted neuronal excitability and plasticity within limbic structures of the brain …

While the dopamine hypothesis has dominated schizophrenia research for several decades,
more recent studies have highlighted the role of fast synaptic transmitters and their receptors …

BACKGROUND: Translational research suggests that D-cycloserine (DCS), a partial N-
methyl-D-aspartate (NMDA) receptor agonist, might facilitate fear extinction and exposure …

Objective: Patients with schizophrenia frequently present with negative symptoms and
cognitive impairments for which no effective treatments are known. Agents that act at the …

Objective: This study examined whether d-cycloserine, a partial agonist at the N-methyl-d-
aspartate (NMDA) glutamatergic receptor, enhances the efficacy of behavior therapy for …

Although hypofunction of N-methyl-D-aspartate (NMDA) receptor-mediated
neurotransmission is proposed to play an important role in the pathophysiology of …